๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shenyang
Clinical trial register · China

Clinical Trials in Shenyang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Shengjing Hospital46 General Hospital of Shenyang Military Region33 First Hospital of China Medical University21 China Medical University, China13 AstraZeneca12
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shenyang

419 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
NCT06637163Esophageal Squamous Cell Carcinoma
DrugsBenmelstobart·Paclitaxel·Carboplatin
Shanghai Zhongshan Hospital
Phase 2
100
Shantou, Shenyang, Shanghai, Tianjin, Hangzhou
2024-10-24
Not yet open
Phimumeยฎ Percutaneous Left Ventricular Assist System Study
NCT06639321Coronary Artery Disease
Shanghai NewMed Medical Co., Ltd.
Not applicable
250
Jilin City, Chengdu, Zhengzhou, Wuhan, Changsha, Shenyang
2024-10-14
Recruiting
Effects of Different Occlusion Angles of Disposable Tracheal Blocker on Right One-lung Ventilation
NCT06595043The Direction of Blocker Placement
China Medical University, China
Not applicable
96
Shenyang
2024-10-09
Active, closed
Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer
NCT06464692Colorectal Cancer
DrugTelisotuzumab Adizutecan
AbbVie
Phase 1
31
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanchang, Shenyang, Hangzhou
2024-09-30
Recruiting
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
NCT06580301B-cell Acute Lymphoblastic Leukemia
DrugYK012
Excyte Biopharma Ltd
Phase 1/2
46
Guangzhou, Guiyang, Zhengzhou, Xuzhou, Nanchang, Changchun, Dalian, Shenyang
2024-09-25
Recruiting
HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC
NCT06632093BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy, Lenvatinib
DrugLenvatinib
First Hospital of China Medical University
Observational
84
Shenyang
2024-09-16
Recruiting
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
NCT06288360Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy
DrugsPaclitaxel-albumin·Camrelizumab·Cisplatin
Tongji Hospital
Phase 2
40
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Wuhan, Changsha, Shenyang
2024-09-12
Active, closed
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
NCT06487559Hepatocellular Carcinoma (HCC)
DrugsLivmoniplimab·Budigalimab
AbbVie
Phase 1
3
Beijing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanchang, Shenyang
2024-09-11
Recruiting
Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
NCT06577519Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
DrugClopidogrel
Jiangsu vcare pharmaceutical technology co., LTD
Phase 3
1,000
Shenyang
2024-09-06
Active, closed
Timing of Endoscopy in Cirrhotic Patients With Acute Variceal Bleeding
NCT06031402Acute Upper Gastrointestinal Bleeding, Acute Variceal Bleeding
General Hospital of Shenyang Military Region
Not applicable
368
Shenyang
2024-09-04
Recruiting
Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
NCT06128252Gastric Cancer
DrugsXelox·Serplulimab
Tang-Du Hospital
Not applicable
96
Wuhan, Nanjing, Shenyang, Xi'an, Chengdu, รœrรผmqi, Chongqing, Shanghai
2024-09-01
Active, closed
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
NCT06116136MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
DrugsS095029·Pembrolizumab
Servier Bio-Innovation LLC
Phase 1/2
48
Beijing, Harbin, Zhengzhou, Shenyang, Jinan, Shanghai, Hangzhou
2024-08-31
Recruiting
SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer
NCT06340230HR Positive/HER2 Low Breast Cancer
DrugsTrastuzumab Rezetecan·Adebrelimab
Shengjing Hospital
Phase 2
93
Shenyang
2024-08-23
Active, closed
HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC
NCT06632106Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor, Immune Checkpoint Inhibitors, Hepatocellular Carcinoma (HCC)
First Hospital of China Medical University
Observational
97
Shenyang
2024-08-16
Active, closed
Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers
NCT06531512Diabetic Foot Ulcer
Oneness Biotech Co., Ltd.
Phase 2/3
120
Jiangmen, Luoyang, Suzhou, Zhenjiang, Shenyang, Xi'an, Hangzhou, Guangzhou
2024-08-16
Recruiting
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
NCT06504732Stomach Neoplasms, Solid Tumor
DrugTrastuzumab
SUNHO๏ผˆChina๏ผ‰BioPharmaceutical CO., Ltd.
Phase 2/3
574
Harbin, Shenyang
2024-08-15
Recruiting
Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
NCT06480864Small Cell Lung Cancer
Yunpeng Liu
Not applicable
38
Shenyang
2024-08-09
Recruiting
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534Crohn's Disease
DrugUpadacitinib
AbbVie
Phase 3
110
Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai, Hangzhou
2024-08-08
Recruiting
The Influence of Climate and Air Pollution on Physical Activity of Chinese People in Shenyang and Shenzhen
NCT07523659Physical Activity, Climate, Air Pollution
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Observational
124
Shenzhen, Shenyang
2024-08-01
Recruiting
A Hierarchical Multi-modal AI Framework for Pathological and Genetic Subtyping of Lung Cancer Based on PET/CT Imaging
NCT07463300Lung Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
5,500
Guangzhou, Wuhan, Yangzhou, Shenyang, Chengdu, Hangzhou
2024-08-01
Recruiting
Efficacy and Safety of Local Glucocorticoids for the Treatment of Acute Radiation-Induced Intestinal Injury
NCT06410443Radiation-Induced Intestinal Injury
DrugDexamethasone
General Hospital of Shenyang Military Region
Not applicable
60
Shenyang
2024-08-01
Recruiting
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
NCT06386146Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
144
Beijing, Guangzhou, Zhengzhou, Shenyang, Jinan, Shanghai
2024-07-24
Recruiting
Multicenter Real-World Study of Hyperthermia in Warts of Special Population
NCT06827938Warts
First Hospital of China Medical University
Not applicable
400
Shenyang
2024-07-10
Recruiting
ARTEMIS-008๏ผšHS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
NCT06498479Small Cell Lung Cancer
DrugsHS-20093·Topotecan
Hansoh BioMedical R&D Company
Phase 3
460
Beijing, Harbin, Zhengzhou, Changchun, Shenyang, Jinan, Shanghai, Guangzhou
2024-07-04
Recruiting
Effects of Different Inhaled Oxygen Concentrations on Lung Function in Older Patients After Laparoscopic Gastrointestinal Surgery Under General Anesthesia
NCT06359106Oxygenation Index
China Medical University, China
Phase 4
1,176
Shenyang, Beijing, Chendu, Chifeng, Dalian, Harbin, Jinan, Kunming
2024-07-02
Recruiting
OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time
NCT06216821Acute Coronary Syndrome
Shenyang Northern Hospital
Not applicable
3,490
Shenyang
2024-07-02
Recruiting
Change in Serum Biomarkers After Endovascular Treatment for Acute Anterior Circulation Large Vessel Occlusion
NCT06383182Ischemic Stroke
General Hospital of Shenyang Military Region
Observational
800
Shenyang
2024-07-02
Not yet open
Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma
NCT06463548Biliary Tract Carcinoma
DrugsIrinotecan Hydrochloride Liposome·Lenvatinib·Capecitabine
Yunpeng Liu
Not applicable
30
Shenyang
2024-07-01
Recruiting
Efficacy and Safety of the Liquid Embolic System (Tonbridge) for Endovascular Treatment of Cerebrovascular Malformations
NCT06479343Intracranial Arteriovenous Malformations
Ton-Bridge Medical Tech. Co., Ltd
Not applicable
170
Guangzhou, Zhengzhou, Nanjing, Changchun, Shenyang, Jinan, Beijing, Chengdu
2024-06-27
Active, closed
A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)
NCT06433531Generalized Pustular Psoriasis
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
9
Beijing, Guangzhou, Shijiazhuang, Shenyang, Chengdu, Hangzhou
2024-06-19
Active, closed
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
NCT05562947Neovascular Age-related Macular Degeneration, nAMD
DrugRanibizumab
Hoffmann-La Roche
Phase 3
68
Beijing, Chengdu, Guangzhou, Harbin, Qingdao, Shanghai, Shenyang, Taiyuan
2024-06-17
Recruiting
Multimodal Magnetic Resonance Imaging in Evaluation of Diabetic Kidney Disease
NCT06452862Diabetic Kidney Disease
Shengjing Hospital
Observational
150
Shenyang
2024-06-06
Active, closed
SGLT2-inhibitors on PC-AKI
NCT06491953Impact of SGLT2-inhibitors on PC-AKI in ACS Patients Receiving Invasive Strategy
Shenyang Northern Hospital
Observational
3,600
Shenyang
2024-06-01
Recruiting
Effect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke
NCT06170944Stroke, Ischemic
General Hospital of Shenyang Military Region
Not applicable
300
Shenyang
2024-06-01
Active, closed
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
NCT06439576Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
DrugFaricimab
Hoffmann-La Roche
Observational
1,000
Shantou, Luoyang, Shiyan, Xuzhou, Fushun, Panjin, Shenyang, Weifang
2024-05-09
By invitation
A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors
NCT06215846Solid Tumor
DrugBioTTT001
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Phase 1
12
Shenyang
2024-05-07
Active, closed
Evaluation of the Ton-bridge Carotid Stent for Carotid Artery Stenosis
NCT06365697Carotid Artery Stenosis
Ton-Bridge Medical Tech. Co., Ltd
Not applicable
188
Shenyang, Linyi, Qingdao, Jinan, Lishui, Beijing
2024-04-24
Recruiting
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
NCT06288373Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy, Neoadjuvant Chemoimmunotherapy
DrugsCamrelizumab·Nab-paclitaxel·Cisplatin
Tongji Hospital
Phase 2/3
440
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Wuhan, Changsha, Shenyang
2024-04-22
Recruiting
A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies
NCT07011186Myeloid Malignancy
DrugsTQB3909·Azacitidine
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
138
Bengbu, Beijing, Chengde, Harbin, Zhengzhou, Wuhan, Zhuzhou, Shenyang
2024-04-17
Recruiting
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
NCT06233942Advanced Solid Tumor
DrugsTislelizumab·Bevacizumab
BeOne Medicines
Phase 1
308
Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Dalian, Shenyang, Jinan
2024-04-12
Active, closed
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guรฉrin (BCG)
NCT06211764Non-Muscle Invasive Bladder Neoplasms
DrugsTAR-200·Mitomycin C·Gemcitabine
Janssen Research & Development, LLC
Phase 3
272
Beijing, Cheng Du Shi, Chongqing, Guangzhou, Shenyang, Tianjin, Wenzhou, Wuhan
2024-04-09
Active, closed
Application of 68Ga-NODAGA-SNA006 Positron Emission Tomography/Computed Tomography (PET/CT) in Tumors
NCT07059832Cancer
Drug68Ga-NODAGA-SNA006
First Hospital of China Medical University
Phase 1/2
30
Shenyang
2024-04-01
Not yet open
OCT or Angiography Guided De-escalation of DAPT
NCT06339021Optical Coherence Tomography, Dual Antiplatelet Therapy, Antiplatelet De-escalation, Neointimal Coverage
Shenyang Northern Hospital
Phase EARLY_PHASE1
80
Shenyang
2024-04-01
Active, closed
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
NCT06254950Ulcerative Colitis
DrugZasocitinib
Takeda
Phase 2
213
Chongqing, Guangzhou, Changsha, Changzhou, Shenyang, Shanghai, Chengdu, Hangzhou
2024-03-29
Recruiting
Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery
NCT06109454Non-small Cell Lung Cancer
DrugHuaier
Liaoning Cancer Hospital & Institute
Observational
240
Shenyang
2024-03-21
Recruiting
Antifungal Agents and Infrared Thermotherapy Alone or in Combination in the Treatment of Sporotrichosis
NCT06300138Sporotrichosis
First Hospital of China Medical University
Not applicable
150
Shenyang
2024-03-15
Recruiting
A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis
NCT06587685Atopic Dermatitis
Prime Gene Therapeutics Co., Ltd.
Phase 3
472
Shenyang
2024-03-15
Active, closed
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer
DrugsBGB-43395·Fulvestrant
BeiGene
Phase 1
103
Beijing, Guangzhou, Harbin, Changsha, Shenyang, Xi'an
2024-03-11
Recruiting
Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China
NCT06414655Twin Pregnancy, Antepartum Condition or Complication, Twin to Twin Transfusion as Antepartum Condition, Pre-Term, Pre-Eclampsia
Peking University Third Hospital
Observational
2,000
Hefei, Beijing, Chongqing, Guangzhou, Shenyang, Jinan, Shanghai, Tianjin
2024-03-01
Active, closed
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
NCT06241118Dermatitis Atopic
DrugsPimecrolimus·Amlitelimab·Tacrolimus
Sanofi
Phase 3
464
Changchun, Chongqing, Guangzhou, Hangzhou, Nanyang, Ningbo, Shanghai, Shenyang
2024-02-29
Recruiting
A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants
NCT06775405Respiratory Synctial Virus Infections
DrugZiresovir
Shanghai Ark Biopharmaceutical Co., Ltd.
Phase 3
180
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Sanya, Shanghai, Shenyang
2024-02-29
Recruiting
Clinical Outcomes of Patients With Coronary Artery Disease
NCT06216847Coronary Heart Disease (CHD)
Shenyang Northern Hospital
Observational
10,000
Shenyang
2024-02-21
Not yet open
Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer
NCT06202313Triple Negative Breast Cancer
DrugsEribulin·Cadonilimab
Shengjing Hospital
Phase 2
128
Shenyang
2024-02-10
Active, closed
A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
NCT06198751Breast Cancer
DrugTQB2102
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
104
Chongqing, Fuzhou, Guiyang, Harbin, Changsha, Shenyang, Shanghai
2024-02-05
Recruiting
Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation
NCT06243354Safety, Tolerability, Efficacy
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase 1/2
257
Fuzhou, Changsha, Shenyang, Jinan, Shanghai, Chengdu
2024-02-04
Recruiting
Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer
NCT06566755Colorectal Cancer
DrugCadonilimab
Caigang Liu
Phase 3
30
Shenyang
2024-02-01
Recruiting
Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers
NCT06188624Advanced Cancer
DrugTQB2922
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
150
Chongqing, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Dalian, Shenyang
2024-02-01
Recruiting
Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2)
NCT06010628Stroke, Ischemic
General Hospital of Shenyang Military Region
Phase 4
1,440
Shenyang
2024-02-01
Recruiting
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
NCT06758557Advanced NSCLC, Advanced Endometrial Cancer
Huabo Biopharm Co., Ltd.
Phase 1/2
282
Baoding, Harbin, Luoyang, Zhengzhou, Lianyungang, Shenyang, Jinan, Linyi
2024-01-31
Active, closed
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT06260163Colitis, Ulcerative
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
112
Beijing, Changzhou, Hangzhou, Shanghai, Shenyang, Zhengzhou
2024-01-19
Active, closed
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
NCT06163326Vitiligo
DrugRitlecitinib
Pfizer
Phase 3
394
Guangzhou, Wuhan, Shenyang, Shanghai, Kunming
2024-01-19
Recruiting
A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors
NCT06101082Solid Tumor
China Medical University, China
Phase 1
9
Shenyang
2024-01-16
Recruiting
A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
NCT06219356Non-Hodgkin Lymphoma
Hangzhou GluBio Pharmaceutical Co., Ltd.
Phase 1
110
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Shenyang
2024-01-11
Recruiting
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
NCT06155396Cervical Cancer
RemeGen Co., Ltd.
Phase 2
116
Bengbu, Beijing, Chongqing, Nanning, Changsha, Nanchang, Shenyang, Jinan
2024-01-11
Recruiting
Trendelenburg Position for Acute Anterior Circulation Ischemic Stroke With Large Artery Atherosclerosis Etiology (HOPES 3)
NCT06010641Stroke, Acute Ischemic
General Hospital of Shenyang Military Region
Not applicable
600
Shenyang
2024-01-10
Recruiting
Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
NCT06282796Breast Cancer
First Hospital of China Medical University
Observational
600
Fuzhou, Dalian, Shenyang, Chengdu
2024-01-01
Recruiting
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
NCT06090539Relapsed/Refractory Non-Hodgkin Lymphoma
DrugsGolcadomide·Mosunetuzumab·Epcoritamab·Rituximab
Bristol-Myers Squibb
Phase 1/2
460
Beijing, Guangzhou, Zhengzhou, Suzhou, Nanchang, Shenyang, Shanghai, Hangzhou
2023-12-29
Recruiting
a PROspective Case Control Study to Develop and Validate a Blood Test FOr mUlti-caNcers Early Detection๏ผˆPROFOUND๏ผ‰
NCT06217900Cancer
Shanghai Weihe Medical Laboratory Co., Ltd.
Observational
16,666
Beijing, Changchun, Guangzhou, Hangzhou, Shenyang
2023-12-28
Recruiting
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
NCT06235229Multiple Myeloma
DrugAZD0120
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1/2
110
Beijing, Hangzhou, Jinan, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an
2023-12-26
Recruiting
MRE for Assessment of Histopathological Growth Patterns in Colorectal Liver Metastases
NCT06208397Metastatic Colorectal Cancer
Shengjing Hospital
Observational
50
Shenyang
2023-12-24
Recruiting
Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC )
NCT06249308Ovarian Cancer
Fudan University
Observational
168
Guangzhou, Shenyang, Shanghai
2023-12-18
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05995353Crohn's Disease
DrugRisankizumab
AbbVie
Phase 3
110
Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2023-12-11
Recruiting
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
NCT06106945Multiple Myeloma
DrugsElranatamab·Pomalidomide·Dexamethasone
AstraZeneca
Phase 1/2
226
Beijing, Changsha, Guangzhou, Shenyang
2023-12-05
Recruiting
Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia
NCT05998759Connective Tissue Diseases, Thrombocytopenia
DrugTelitacicept
Beijing Hospital
Phase 2
296
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Hohhot, Shenyang
2023-12-02
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shenyang, Shanghai
2023-12-01
Recruiting
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06095583Limited-stage Small Cell Lung Cancer (LS-SCLC)
DrugToripalimab
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
756
Harbin, Changsha, Nanchang, Shenyang, Jinan, Anyang, Beijing, Changchun
2023-11-15
Recruiting
Comparing Myopia Treatments in Youth: Defocus Spectacles, Glasses, and Ortho-K
NCT06278974Myopia, Cost-effectiveness Analysis, Quality of Life
He Eye Hospital
Observational
90
Shenyang
2023-11-10
Recruiting
Clinical Research on the Treatment Model of Ambulatory Surgery for Colorectal Cancer
NCT06637215Colorectal Carcinoma, Day Surgery
First Hospital of China Medical University
Not applicable
352
Shenyang
2023-11-01
Not yet open
Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations
NCT06118658Gastric, Colorectal Adenocarcinoma
DrugTislelizumab
China Medical University, China
Phase 2
30
Shenyang
2023-11-01
Active, closed
Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old
NCT06058416Hepatitis A
Sinovac Biotech Co., Ltd
Phase 4
1,092
Shenyang
2023-10-24
Active, closed
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenstrรถm Macroglobulinemia
NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 2
114
Xiamen, Guangzhou, Zhengzhou, Wuhan, Yancheng, Shenyang, Qingdao, Shanghai
2023-10-23
Recruiting
Nutritional Intervention for Patients With Multiple Cancer Types
NCT06059560Cancer
First Hospital of China Medical University
Not applicable
1,000
Shenyang
2023-10-01
Recruiting
Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC
NCT06165900Stereotactic Radiotherapy, Immunotherapy, Breast Cancer
DrugsAdebrelimab·Carboplatin
Shengjing Hospital
Phase 2
136
Shenyang
2023-09-26
Active, closed
Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment
NCT05132790Breast Cancer
Shengjing Hospital
Not applicable
24
Shenyang
2023-09-25
Recruiting
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
NCT05981703Advanced Solid Tumor, Solid Tumor
DrugTislelizumab
BeOne Medicines
Phase 1
337
Hefei, Harbin, Wuhan, Shenyang, Jining, Yantai, Shanghai, Chengdu
2023-09-21
Recruiting
Recurrent High Grade Glioma Treated by LITT
NCT06161610Recurrent High Grade Glioma
Beijing Tiantan Hospital
Not applicable
135
Beijing, Guangzhou, Zhengzhou, Wuhan, Changchun, Shenyang, Jinan, Shanghai
2023-09-19
By invitation
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
NCT05979441Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis
DrugEfgartigimod PH20
argenx
Phase 3
240
Guangzhou, Nanjing, Beijing, Chengdu, Shanghai, Shenyang, Zhengzhou
2023-09-12
Active, closed
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
NCT05884398Metastatic Castrate-sensitive Prostate Cancer
DrugApalutamide
Janssen Research & Development, LLC
Phase 3
420
Beijing, Changchun, Chengdu, Guangzhou, Jinan, Ningbo, Shenyang, Wuhan
2023-08-31
Active, closed
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
DrugAficamten
Cytokinetics
Phase 3
500
Guangzhou, Beijing, Jilin City, Nanjin, Shanghai, Shenyang, Wuhan, Xi'an
2023-08-31
Recruiting
AK104 for Recurrent or Metastatic Vulvar Cancer
NCT05932212Vulvar Cancer
DrugsCadonilimab·Paclitaxel·Cisplatin·Carboplatin
Akeso
Phase 2
20
Fuzhou, Guangzhou, Shijiangzhuang, Shenyang, Tianjin, Hangzhou
2023-08-25
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589Asthma
DrugTezepelumab
AstraZeneca
Phase 3
231
Beijing, Changchun, Hohhot, Lanzhou, Nanjing, Shanghai, Shenyang, Shenzhen
2023-08-24
Active, closed
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis
NCT06174402Primary Biliary Cholangitis
Han Ying
Phase 2/3
184
Lanzhou, Guangzhou, Nanjing, Shenyang, Xi'an, Yanโ€™an, Kunming, Beijing
2023-08-21
Recruiting
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT05785741Advanced Solid Tumor
DrugsDB-1310·Osimertinib·Trastuzumab·Capecitabine
DualityBio Inc.
Phase 1/2
1,000
Zhengzhou, Changsha, Nanjing, Wuxi, Changchun, Shenyang, Shanghai, Chengdu
2023-08-17
Active, closed
A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure
NCT05824923Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases
Pulnovo Medical (Wuxi) Co., Ltd.
Phase 3
264
Shenyang
2023-08-14
Recruiting
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05924750Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
DrugBL-M11D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
130
Hefei, Beijing, Haerbin, Shenyang, Jinan, Shanghai, Chengdu, Tianjin
2023-08-02
Recruiting
A Clinical Study of Hyperthyroidism in Children
NCT06570967Hyperthyroidism
DrugMethimazole
Shengjing Hospital
Observational
1,000
Shenyang
2023-07-18
Active, closed
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
NCT06009861Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
DrugsAlbumin-Bound Paclitaxel·Tislelizumab·Cisplatin
Peking University Hospital of Stomatology
Phase 2
110
Beijing, Baoding, Tangshan, Harbin, Chifeng, Hohhot, Changchun, Shenyang
2023-06-27
Recruiting
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
NCT05909332Breast Cancer, Triple Negative Breast Cancer
Fudan University
Phase 3
764
Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang
2023-06-20
Active, closed
FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
NCT05913037Neurofibromatosis 1, Plexiform Neurofibroma, NF1
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3
167
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Wuhan, Shenyang, Shanghai, Chengdu
2023-06-20
Active, closed
Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors
NCT05700084Advanced Solid Tumor
DrugsUtidelone·Capecitabine
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 1/2
84
Beijing, Chengdu, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang, Wuhan
2023-06-09
Rows per page Showing 201–300 of 419
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/shenyang?page=3

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 419 of those studies with a site in Shenyang.

How many clinical trials are recruiting in Shenyang?

253 of the 419 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 55 have not yet opened recruitment, 101 are active but closed to new participants, and 10 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.